EP0203970A1 - Transmissible, mammalian genes associated with tumor metastasis - Google Patents
Transmissible, mammalian genes associated with tumor metastasisInfo
- Publication number
- EP0203970A1 EP0203970A1 EP85906133A EP85906133A EP0203970A1 EP 0203970 A1 EP0203970 A1 EP 0203970A1 EP 85906133 A EP85906133 A EP 85906133A EP 85906133 A EP85906133 A EP 85906133A EP 0203970 A1 EP0203970 A1 EP 0203970A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- metastasis
- dna
- tumor
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 132
- 206010027476 Metastases Diseases 0.000 title claims abstract description 105
- 230000009401 metastasis Effects 0.000 title claims abstract description 77
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 51
- 241000124008 Mammalia Species 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 144
- 108020004414 DNA Proteins 0.000 claims description 120
- 239000003550 marker Substances 0.000 claims description 54
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 46
- 230000001394 metastastic effect Effects 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 29
- 238000001890 transfection Methods 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 239000000523 sample Substances 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 7
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- 108091023043 Alu Element Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 230000003042 antagnostic effect Effects 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 230000008485 antagonism Effects 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 4
- 230000004044 response Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000004513 sizing Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract description 4
- 210000002747 omentum Anatomy 0.000 abstract description 2
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 47
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 238000011081 inoculation Methods 0.000 description 17
- 108700020796 Oncogene Proteins 0.000 description 13
- 108700042226 ras Genes Proteins 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 206010005003 Bladder cancer Diseases 0.000 description 8
- 201000001531 bladder carcinoma Diseases 0.000 description 8
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 6
- 102100029974 GTPase HRas Human genes 0.000 description 5
- 102000043276 Oncogene Human genes 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 102000016914 ras Proteins Human genes 0.000 description 4
- 108010014186 ras Proteins Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 101710113436 GTPase KRas Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 231100000588 tumorigenic Toxicity 0.000 description 3
- 230000000381 tumorigenic effect Effects 0.000 description 3
- 241000880621 Ascarina lucida Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 108700024542 myc Genes Proteins 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000007099 Yamamoto allylation reaction Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 101150038738 ble gene Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000018529 duodenal adenocarcinoma Diseases 0.000 description 1
- 201000005839 duodenum adenocarcinoma Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 230000008883 metastatic behaviour Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Definitions
- DNAs from two of the four metastases derived from the secondary transfectants were digested with the restriction endonucleases EcoRI, BamHI, and Hindlll. Digested DNAs were religated with genomic NIH 3T3 DNA. The resulting DNAs were then co ⁇ transfected with pSV2neo DNA into EJ-6-2-Bam-6 ' a cells and placed under G418 selection. Cells selected were inoculated subcutaneously into NFS/NCr mice (10 cells/mouse) . Two to six weeks later, mice were examined for metastasis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67662584A | 1984-11-30 | 1984-11-30 | |
| US676625 | 1991-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0203970A1 true EP0203970A1 (en) | 1986-12-10 |
Family
ID=24715276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP85906133A Withdrawn EP0203970A1 (en) | 1984-11-30 | 1985-11-26 | Transmissible, mammalian genes associated with tumor metastasis |
Country Status (13)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049662A (en) * | 1987-10-13 | 1991-09-17 | The United States Of America As Represented By The Department Of Health And Human Services | Kit for diagnosing cancer metastatic potential |
| ES2164634T3 (es) * | 1989-10-18 | 2002-03-01 | Us Health | Produccion y uso de proteina nm23-h2 humana y anticuerpos previstos a tal efecto. |
| US6825320B1 (en) | 1995-03-29 | 2004-11-30 | Millenium Pharmaceuticals, Inc. | FOHY03 polypeptides |
| US6251597B1 (en) | 1996-03-29 | 2001-06-26 | Millennium Pharmaceuticals, Inc. | Methods for detecting fohy030 |
| US6794185B1 (en) | 1995-03-29 | 2004-09-21 | Millennium Pharmaceuticals, Inc. | fohy030 nucleic acid molecules |
| US5633161A (en) * | 1995-03-29 | 1997-05-27 | Millennium Pharmaceuticals, Inc. | Murine gene fomy030 coding for tumor progression inhibitor |
| US5783182A (en) * | 1996-01-30 | 1998-07-21 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| DE69630142D1 (de) * | 1995-11-16 | 2003-10-30 | Baylor College Medicine | Verfahren zur identifizierung metastatischer sequenzen |
| USRE38490E1 (en) | 1995-11-16 | 2004-04-06 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| WO1997025443A1 (en) * | 1996-01-10 | 1997-07-17 | The University Of Liverpool | Metastasis inducing dna's |
| USRE38392E1 (en) | 1996-01-30 | 2004-01-20 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| US6312909B1 (en) | 1996-03-29 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis prevention and treatment of tumor progression |
| WO1999022773A2 (en) | 1997-11-05 | 1999-05-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
| EP1062340A2 (en) | 1998-03-13 | 2000-12-27 | The Baylor College of Medicine | Compositions and methods for the treatment and prevention of metastatic disorders |
| US7462491B2 (en) | 2002-01-31 | 2008-12-09 | Baylor College Of Medicine | Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin |
-
1985
- 1985-11-26 IL IL77157A patent/IL77157A0/xx unknown
- 1985-11-26 JP JP60505382A patent/JPS62501399A/ja active Pending
- 1985-11-26 FI FI863095A patent/FI863095A0/fi not_active IP Right Cessation
- 1985-11-26 HU HU8667A patent/HUT41837A/hu unknown
- 1985-11-26 WO PCT/US1985/002323 patent/WO1986003226A1/en not_active Application Discontinuation
- 1985-11-26 AU AU51979/86A patent/AU5197986A/en not_active Abandoned
- 1985-11-26 EP EP85906133A patent/EP0203970A1/en not_active Withdrawn
- 1985-11-27 ZA ZA859070A patent/ZA859070B/xx unknown
- 1985-11-27 GR GR852864A patent/GR852864B/el unknown
- 1985-11-29 ES ES549438A patent/ES8705043A1/es not_active Expired
- 1985-11-29 PT PT81584A patent/PT81584B/pt unknown
-
1986
- 1986-07-29 NO NO863066A patent/NO863066L/no unknown
- 1986-07-29 DK DK359486A patent/DK359486A/da not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO8603226A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FI863095L (fi) | 1986-07-29 |
| FI863095A7 (fi) | 1986-07-29 |
| DK359486D0 (da) | 1986-07-29 |
| HUT41837A (en) | 1987-05-28 |
| ES8705043A1 (es) | 1987-04-16 |
| AU5197986A (en) | 1986-06-18 |
| PT81584B (en) | 1987-04-07 |
| DK359486A (da) | 1986-07-29 |
| NO863066L (no) | 1986-09-29 |
| GR852864B (enrdf_load_stackoverflow) | 1986-03-28 |
| ZA859070B (en) | 1986-07-30 |
| IL77157A0 (en) | 1986-04-29 |
| JPS62501399A (ja) | 1987-06-11 |
| ES549438A0 (es) | 1987-04-16 |
| NO863066D0 (no) | 1986-07-29 |
| FI863095A0 (fi) | 1986-07-29 |
| PT81584A (en) | 1985-12-01 |
| WO1986003226A1 (en) | 1986-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mulligan et al. | Factors governing the expression of a bacterial gene in mammalian cells | |
| EP0203970A1 (en) | Transmissible, mammalian genes associated with tumor metastasis | |
| Shih et al. | Isolation of a transforming sequence from a human bladder carcinoma cell line | |
| US5814476A (en) | Process for the production of stochastically-generated transcription or translation products | |
| Smithies et al. | Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination | |
| EP0174810B1 (en) | Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein dna | |
| EP0518650B1 (en) | Sequence specific DNA binding by P53 | |
| Snyder et al. | [7] λgt 11: Gene isolation with antibody probes and other applications | |
| Lai et al. | Deletion mutants of simian virus 40 generated by enzymatic excision of DNA segments from the viral genome | |
| US5763192A (en) | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique | |
| US4535058A (en) | Characterization of oncogenes and assays based thereon | |
| EP0346710B1 (en) | cDNAs coding for members of the carcinoembryonic antigen family | |
| Clayton et al. | Cloning and characterization of the integrated viral DNA from three lines of SV40-transformed mouse cells | |
| Young et al. | Bacteriophage T4 gene transcription studied by hybridization to cloned restriction fragments | |
| US4725550A (en) | Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma | |
| Fang et al. | Translocation breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal adenocarcinoma | |
| Lee et al. | Structural alterations in the long terminal repeat of an acquired mouse mammary tumor virus provirus in a T-cell leukemia of DBA/2 mice | |
| US6184032B1 (en) | Identification of genes encoding cell surface antigens using CREF-Trans 6 cells | |
| Stanners et al. | Cloning of a functional gene responsible for the expression of a cell surface antigen correlated with human chronic lymphocytic leukemia | |
| Fisher et al. | Wilms' tumor-aniridia association: segregation of affected chromosome in somatic cell hybrids, identification of cell surface antigen associated with deleted area, and regional mapping of c-Ha-ras-1 oncogene, insulin gene, and beta-globin gene | |
| Ruddle et al. | DNA-mediated gene transfer in mammalian gene cloning | |
| Wang et al. | Polymerization of vector DNA after transfection into hamster fibroblast cells | |
| US6159751A (en) | Development of DNA probes and immunological reagents of human tumor associated antigens | |
| EP0873424B1 (en) | Metastasis inducing dna's | |
| CA1290712C (en) | Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein dna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
| 17P | Request for examination filed |
Effective date: 19861110 |
|
| 17Q | First examination report despatched |
Effective date: 19880729 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19881215 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BERNSTEIN, SHELLY, C. Inventor name: WEINBERG, ROBERT, A. |